Table III Diagnostic sensitivities of LAMC2, CA19.9, and LAMC2+CA19.9 at targeted specificities
CohortComparison groupSensitivity at 80% specificitySensitivity at 90% specificity
LAMC2CA19.9LAMC2+CA19.9LAMC2CA19.9LAMC2+CA19.9
JapanBenign (n = 49) vs. PDAC (n = 50)0.620.780.840.540.720.80
GermanyControl (n = 50) vs. PDAC (n = 100)0.610.810.860.450.790.80
Benign (n = 50) vs. PDAC (n = 100)0.430.720.720.320.610.58
USControl (n = 20) vs. PDAC-stageIIB (n = 25)0.720.800.800.560.600.68
Control (n = 20) vs. PDAC-stageIV (n = 25)0.760.880.900.680.880.88
Benign (n = 15) vs. PDAC-stageIIB (n = 25)0.760.500.700.590.330.46
Benign (n = 15) vs. PDAC-stageIV (n = 25)0.780.800.880.570.720.77